Hemophilia B Gene Therapy Market Report 2026

The hemophilia b gene therapy market size has grown exponentially in recent years. It will grow from $0.55 billion in 2025 to $0.71 billion in 2026 at a compound annual growth rate (CAGR) of 29.6%. The growth in the historic period can be attributed to improvements in gene delivery technologies, increased understanding of hemophilia b genetics, expansion of clinical research programs, rising burden of lifelong replacement therapy, availability of specialized treatment centers.

The hemophilia b gene therapy market size is expected to see exponential growth in the next few years. It will grow to $2.01 billion in 2030 at a compound annual growth rate (CAGR) of 29.8%. The growth in the forecast period can be attributed to increasing approvals of gene therapies, rising investments in rare disease treatments, growing demand for durable therapeutic outcomes, expansion of advanced manufacturing capabilities, increasing patient access programs. Major trends in the forecast period include increasing progress in one-time curative therapies, rising focus on long-term factor ix expression, growing optimization of aav vector design, expansion of personalized gene therapy approaches, enhanced regulatory alignment for advanced therapies.

The increasing number of gene therapy clinical trials is expected to drive the growth of the hemophilia B gene therapy market in the coming years. Gene therapy clinical trials are research studies conducted to assess the safety, effectiveness, and long-term therapeutic potential of gene-based treatments in human participants. The rise in gene therapy clinical trials is fueled by growing investments from biopharmaceutical companies, advances in viral vector technologies, supportive regulatory environments, and the need to address rare genetic disorders with significant unmet medical needs, including hemophilia B. Hemophilia B gene therapy benefits from this expanding gene therapy clinical trial landscape by utilizing established clinical development pathways, accumulated regulatory expertise, and manufacturing capabilities linked to in vivo gene delivery approaches. For example, in January 2026, according to the Bioindustry Association (BIA), a UK-based national trade association, the UK recorded 193 ongoing advanced therapy clinical trials, broadly comparable to 2024 levels, with more than half in early stages, approximately 80% commercially sponsored, and over 80% focused on gene therapies, evenly divided between ex vivo and in vivo approaches. Therefore, the increasing number of cell and gene therapy clinical trials is driving the growth of the hemophilia B gene therapy market.

The growing adoption of personalized medicine is expected to propel the growth of the hemophilia B gene therapy market going forward. Personalized medicine is a medical approach that customizes disease prevention, diagnosis, and treatment based on an individual’s genetic, molecular, or clinical characteristics to enhance therapeutic outcomes and minimize adverse effects. The rising adoption of personalized medicine is driven by advances in genomics, improved identification of biomarkers, and expanding regulatory support for targeted therapies that move away from one-size-fits-all treatment models. Hemophilia B gene therapy closely aligns with the principles of personalized medicine by addressing the underlying genetic cause of the disease and enabling long-term therapeutic benefits through individualized gene-based interventions. These therapies depend on patient-specific genetic and clinical profiling to determine treatment eligibility, optimize dosing strategies, and monitor long-term safety and durability. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023. Therefore, the increasing adoption of personalized medicine is contributing to the growth of the hemophilia B gene therapy market.

Leading companies operating in the hemophilia B gene therapy market are increasingly focusing on innovations in next-generation gene delivery platforms, particularly optimized adeno-associated virus (AAV)-based vector systems, to enhance therapeutic efficacy and safety. Optimized AAV-based vector systems serve as advanced viral delivery platforms that enable efficient and controlled transfer of functional clotting factor IX genes into target hepatocytes, supporting long-term endogenous factor production. For example, in May 2023, CSL Behring GmbH, a Germany-based biotechnology company, received European Commission approval for HEMGENIX, the first gene therapy approved for the treatment of hemophilia B. HEMGENIX is indicated for adult patients with severe or moderate hemophilia B without a history of factor IX inhibitors and is designed to reduce or eliminate the need for routine factor IX prophylaxis. According to results from the pivotal HOPE-B clinical study, a significant proportion of treated patients no longer required regular factor IX infusions, demonstrating sustained therapeutic benefit and highlighting the potential of next-generation AAV-based gene therapies in long-term disease management.

Major companies operating in the hemophilia b gene therapy market are REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.

Tariffs are influencing the hemophilia B gene therapy market by increasing costs of imported viral vectors, bioprocessing equipment, reagents, and specialized laboratory instruments used in therapy development and manufacturing. Research institutions and biopharmaceutical companies in North America and Europe are most affected due to dependence on global supply chains, while Asia-Pacific faces higher costs for clinical trial materials. These tariffs are raising development expenses and extending commercialization timelines. However, they are also encouraging regional biomanufacturing investments, localized vector production, and domestic capability building in advanced gene therapy technologies.

The hemophilia b gene therapy market research report is one of a series of new reports that provides hemophilia b gene therapy market statistics, including hemophilia b gene therapy industry global market size, regional shares, competitors with a hemophilia b gene therapy market share, detailed hemophilia b gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the hemophilia b gene therapy industry. This hemophilia b gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hemophilia B gene therapy refers to an advanced treatment approach in which a functional factor IX (F9) gene is delivered into a patient’s liver cells, most commonly using an adeno-associated viral (AAV) vector, enabling the body to produce its own clotting factor on a sustained basis. This therapy is designed to address the root genetic cause of the disorder and significantly reduce bleeding episodes and lifelong dependence on regular factor IX replacement infusions through a single or long-lasting treatment.

The primary types of hemophilia B gene therapy include adeno-associated viral (AAV) vectors, lentiviral vectors, and retroviral vectors. Adeno-associated viral (AAV) vectors are viral delivery platforms engineered to transport functional copies of the factor IX gene into patient cells to reestablish normal blood clotting activity. These therapies address disease severities such as severe hemophilia B, moderate hemophilia B, and mild hemophilia B. They are offered through treatment approaches including on-demand therapy, curative therapy, and prophylactic therapy, and are administered across patient age groups encompassing geriatric, adult, and pediatric populations. Distribution of these therapies occurs through hospital pharmacies and specialty pharmacies.

The hemophilia B gene therapy market includes revenues earned by entities through gene therapy research and development, vector design and optimization services, clinical trial management services, patient screening and eligibility assessment services, genetic testing and sequencing services, and regulatory consulting and approval services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.